Abstract:
In addition to liquid-based cytology (LBC) and HR HPV testing, p16/ki-67 dual-staining is another method for cervical cancer screening. The combination of any two methods can improve the accuracy of screening, but some cervical lesions are still missed or misdiagnosed. In this retrospective study, the significance of LBC, HR HPV testing and especially p16/ki-67 dual-staining in cervical lesion screening was evaluated with reference to histological diagnosis. At the same time, we tried to explore the value of p16/ki-67 dual-staining combined with LBC and HR HPV testing (triple detection) in improving the diagnostic specificity of CIN2+ and reducing the missed diagnosis of CIN2+ lesions. We found that p16/ki-67 dual-staining was valuable in identifying cervical CIN2+ lesions and reducing the missed diagnosis of CIN2+ in HPV negative patients. More than 96% of CIN2+ patients were positive for two or three tests of triple detection. Whole positive triple detection can effectively predict high grade cervical lesions. In conclusion, the triple detection can distinguish almost all cervical CIN2+ lesions. Our data put forward and highlight the feasibility and significance of triple detection in cervical lesion screening.
摘要:
除了液基细胞学(LBC)和HRHPV检测,p16/ki-67双重染色是宫颈癌筛查的另一种方法。任何两种方法的结合都可以提高筛选的准确性,但仍有部分宫颈病变漏诊或误诊。在这项回顾性研究中,LBC的意义,参考组织学诊断,评估了HRHPV检测,尤其是p16/ki-67双重染色在宫颈病变筛查中的应用。同时,我们试图探讨p16/ki-67双重染色联合LBC和HRHPV检测(三重检测)在提高CIN2+诊断特异性和减少CIN2+病变漏诊中的价值.我们发现p16/ki-67双重染色在确定宫颈CIN2病变和减少HPV阴性患者CIN2的漏诊方面具有重要价值。超过96%的CIN2患者对两次或三次三重检测呈阳性。整体阳性三联检测能有效预测宫颈高级别病变。总之,三重检测可以区分几乎所有宫颈CIN2+病变。我们的数据提出并强调了三联检测在宫颈病变筛查中的可行性和意义。